RMTI (Rockwell Medical) Current Deferred Revenue: $0.36 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

RMTI Rockwell Medical Inc RMTI
48 GF Score
Price $7.49
GF Value $8.31
Valuation Modestly Undervalued
! 2 Warning Signs
View Full Analysis

What is Rockwell Medical Current Deferred Revenue?

Rockwell Medical RMTI -5.30% 48 Current Deferred Revenue is $0.36 Mil as of Jun. 2026. GuruFocus rates RMTI with a GF Score™ of 48/100 and a GF Value™ of $8.31 (Modestly Undervalued). The stock has 2 warning signs investors should review.

Current Deferred Revenue represents collections of cash or other assets related to revenue producing activity for which revenue has not yet been recognized. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP. It can be either current or non-current item. Also called unearned revenue.

Rockwell Medical's current deferred revenue for the quarter that ended in Jun. 2026 was $0.36 Mil.

Rockwell Medical Current Deferred Revenue Related Terms

Rockwell Medical Current Deferred Revenue Historical Data

* Premium members only.

The historical data trend for Rockwell Medical's Current Deferred Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Rockwell Medical Current Deferred Revenue Chart

Rockwell Medical Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Current Deferred Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2.32 1.80 0.29 0.14 0.36

Rockwell Medical Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Current Deferred Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.11 0.20 0.36 0.07 0.36
RMTI
48GF Score
Rockwell Medical Inc RMTI
Current Deferred Revenue is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Current Deferred Revenue of $0.36 Mil mean?
Rockwell Medical (RMTI) has a Current Deferred Revenue of $0.36 Mil as of Jun. 2026. Current Deferred Revenue records the total amount of cash received for unfinished services. View historical data on Rockwell Medical and its competitors.
Is Rockwell Medical's Current Deferred Revenue too high?
Rockwell Medical's current Current Deferred Revenue is $0.36 Mil. Overall, Rockwell Medical has a GF Score™ of 48/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Rockwell Medical's Current Deferred Revenue compare to BTAI and MRMD?
Rockwell Medical's Current Deferred Revenue of $0.36 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Deferred Revenue for a Drug Manufacturers company?
A good Current Deferred Revenue depends on the Drug Manufacturers industry context. However, Current Deferred Revenue should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Deferred Revenue mean?
A high Current Deferred Revenue can signal that a stock is expensive relative to its fundamentals. Current Deferred Revenue records the total amount of cash received for unfinished services. View historical data on Rockwell Medical and its competitors. Rockwell Medical's current Current Deferred Revenue is $0.36 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Rockwell Medical stock overvalued right now?
Based on GuruFocus' analysis, Rockwell Medical (RMTI) is currently considered Modestly Undervalued. The stock's GF Value™ is $8.31, compared to a current price of $7.49 — trading 9.9% below its estimated fair value. The current Current Deferred Revenue is $0.36 Mil. Rockwell Medical's overall GF Score™ is 48/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Deferred Revenue calculated?
Current Deferred Revenue is calculated from a company's financial statements. For Rockwell Medical (RMTI), the current Current Deferred Revenue is $0.36 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Rockwell Medical (RMTI) Overvalued in 2026?

Based on GuruFocus' analysis, Rockwell Medical stock appears to be undervalued. The current stock price of $7.49 is trading 9.9% below its estimated GF Value™ of $8.31. GuruFocus considers Rockwell Medical to be Modestly Undervalued.

Key valuation signals for RMTI:

  • Current Deferred Revenue: $0.36 Mil
  • GF Value™: $8.31 vs. price of $7.49 (9.9% below fair value)
  • GF Score™: 48/100 with 2 warning signs

No single metric tells the full story. See the RMTI stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Rockwell Medical Business Description

Other Exchanges RWMA:Germany
Address 30142 South Wixom Road, Wixom, MI, USA, 48393
Rockwell Medical Inc is a healthcare company that develops, manufactures, commercializes, and distributes a portfolio of hemodialysis products for dialysis providers. It is a supplier of liquid bicarbonate concentrates, acid, and dry bicarbonate concentrates for dialysis patients in the United States. The company's products include CitraPure citric acid concentrate, RenalPure liquid acid concentrate, and SteriLyte bicarbonate concentrate, among others. The company delivers the majority of its hemodialysis concentrates products and mixers to dialysis clinics throughout the United States and internationally, utilizing its own delivery trucks and third-party carriers.
48GF Score

Get the complete analysis for RMTI

Current Deferred Revenue is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$7.49
Price
$8.31
GF Value